BioLeaders

Chief Executive Officer, SynaptixBio (July 2023) Dan Williams is an accomplished biopharmaceuticals leader with two decades of industrial experience from bench to operational and scientific executive roles. During his career Dan has served as Vice President of Research Operations at Adaptimmune PLC. and Chief Product Officer at Meatable B.V. Dr. Williams is the CEO and co-founder of SynaptixBio LTD., a developer of therapeutics to treat TUBB4A leukodystrophy. Key milestones in your career journey to date? The decision to keep my education broad, including my PhD from Dundee, proved invaluable; along with being in the right place at the right [...]

Managing Partner, Jeito Capital (July 2023) Sabine Dandiguian is Managing Partner at Jeito Capital and has over 30 years of experience in the pharmaceutical and medical devices industry. These years of experience have enabled her to acquire in-depth operational and strategic capacities, particularly in market access, innovative "business models" and management. She has spent the last 20 years at Johnson & Johnson, in operational positions of increasing responsibility, notably at Janssen (Johnson & Johnson's pharmaceutical sector) as President France in 2005, then Managing Director of European emerging countries, in charge of a cluster covering Russia, Turkey, the Middle East [...]

Chief Executive Officer, Engimmune Therapeutics (June 2023) Lars Nieba serves as CEO of Engimmune Therapeutics, a biotech company developing soluble, multispecific TCRs as therapy for solid tumours and auto-immune diseases. Lars brings more than 25 years of leadership experience in the development of several pharmaceutical products and innovative technologies. He was CTO and CEO at Nordic Nanovector, a biotech company developing novel radio-immunoconjugates for treating cancers, before that he served as VP and Strategic Product Lead at Bayer and held several leadership roles at F. Hoffmann-La Roche responsible for clinical operations, clinical supply planning, biologics technology and business development. [...]

Chief Executive Officer, Nykode Therapeutics (May 2023) Michael Engsig joined Nykode Therapeutics in 2017. He is a broadly anchored pharmaceutical professional with extensive experience, from early-stage drug discovery to late-stage development and product launches in biotech and pharma and across all major geographical areas. His career history includes specialist and managerial roles at Takeda and Nycomed. Michael holds a civil engineering (MSc) degree in chemistry specializing in biotechnology from the Technical University of Denmark, and a Graduate Diploma in Business Administration (HD) in organization and leadership from the Copenhagen Business School (CBS). Key milestones in your career journey to [...]

Board Director Cantargia AB, Targovax ASA, CytoSeek, Imophoron, Resolys Bio (May 2023) Damian Marron is an experienced Board Chair and Non-Executive Director, corporate advisor and former serial Biotech CEO with a successful track record of value creation through public and venture capital financing, portfolio planning, M&A, licensing agreements and R&D collaborations, both as an executive and in advisory roles. He has notably specialized in immuno-oncology, cell therapy and orphan diseases. Damian is currently Non-Executive Chair of the Board at Targovax ASA, Imophoron Ltd and CytoSeek Ltd and Non-Executive Director at Cantargia AB and Resolys Bio Inc. He is also [...]

Chief Executive Officer, Stablepharma, Board Director and Investor (April 2023) Özgür Tuncer has over two decades of experience in the biopharmaceutical industry with deep expertise in executive leadership, strategy, M&A and investments. Most recently, he was Global Vice President in IQVIA, leading company’s Financial Investors practice. In that role, Özgür was involved in more than 300 industry-shaping transactions with valuations of $100m-10bn+, working with world’s leading Private Equity & Venture Capital investors. In addition to being the CEO & Executive Director of Stablepharma, Özgür is an investment partner with Ascension Ventures and co-founder of the Ascension Life Fund. In [...]

Chief Executive Officer, Oxford Medical Products (April 2023) Oxford Medical Products (OMP) is a clinical staged, VC backed, company providing a non-surgical weight loss product that will redefine the obesity treatment market. Excessive weight affects almost 2 billion people WW, costing the US health system $148bn annually. Our proprietary hydrogel pill is taken orally at home and works like a gastric balloon, without the expense or need for hospital visits. The pills fill 50% of the stomach volume, and stay in the stomach for several weeks, reducing hunger, leading to weight loss. The hydrogel is passed naturally with redosing [...]

Chief Executive Officer, Amphista Therapeutics (March 2023) Nicki has over 25 years’ experience in pharmaceutical and biotechnology R&D in a variety of senior scientific and leadership roles. She was previously VP and Global Head of External Drug Discovery at F. Hoffmann-La Roche Ltd and prior to that, Senior Director, Business Development for GSK’s Centre of Excellence for External Drug Discovery (CEEDD). Nicki’s Biotech experience includes her role as Chair of the Board for Nanna Therapeutics Ltd, founding CEO of VirionHealth and Head of Drug Discovery at Syntaxin Ltd. She holds a PhD in Cell Biology from University College London. [...]

David Reynolds BioLeader Interview - David Reynolds, Chief Executive Officer, LoQus23 Therapeutics, Non-Executive Director, AstronauTx (March 2023) David is a highly experienced pharmaceutical research and development leader having worked for nearly 20 years at Merck Sharp & Dohme, Lundbeck and latterly Pfizer, where he was the Cambridge Neuroscience & Pain Research Site Head. He has held a variety of R&D leadership roles with responsibilities ranging from exploratory biology, through drug discovery, early clinical development and in-licensing in multiple disease areas, with a focus on neuroscience and pain. Before joining the Dementia Discovery Fund he spent three years as the [...]

Matt Regan BioLeader Interview - Matt Regan, Chief Executive Officer, Micreos Pharmaceuticals (February 2023) Senior, international, Healthcare leader with 30-years of research-based Biopharmaceutical & Medical device experience with Global leaders such as Abbott, AbbVie and Novo Nordisk. Currently CEO with the Clinical stage Biotech Company Micreos Pharma. Broad, diverse experience having held leadership roles in Manufacturing, Engineering, Supply Chain management, HR management, Research & Development as well as very significant commercial leadership roles at the Country and Regional level. Authentic, values-driven leader with the ability to inspire large organizations to transform, to build new capabilities, and to raise the [...]